Bharat Biotech on course to have 26,000 volunteers for Phase-3 clinical trials of Covaxin


PTI, Jan 3, 2021, 8:25 AM IST

New Delhi: Bharat Biotech on Saturday said it is moving towards achieving the target of having 26,000 volunteers across the country for Phase-3 trials of its Covid-19 vaccine ”Covaxin”.

The company has already roped in 23,000 volunteers for the trials, it said.

The company statement has come after an expert panel of India’s central drug authority recommended granting permission for the restricted use of Covaxin in an emergency situation, especially in the context of infection by mutant strains.

The recommendation for Bharat Biotech”s vaccine came a day after the panel cleared the Serum Institute of India’s emergency use authorization application for the Oxford-AstraZeneca vaccine Covishield, paving the way for the rollout of COVID-19 shots in the country in the next few days.

Bharat Biotech, Serum Institute, and Pfizer had applied with the Drug Controller General of India (DCGI) for emergency use authorization for their respective vaccines.

The Phase III human clinical trials of Covaxin, which began in mid-November last year, require 26,000 volunteers across India, Bharat Biotech said in a statement.

“This is India’s first and only Phase III efficacy study for a COVID-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India. COVAXIN has been evaluated in around 1,000 subjects in Phase I and Phase II clinical trials, with promising safety and immunogenicity results, with acceptance in international peer-reviewed scientific journals,” it added.

The company has developed the vaccine in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).

This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech”s BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world, it added.

“We thank every volunteer who has taken the time to participate in this trial. Their volunteering spirit is a great morale boost for India and the world. We thank all the principal investigators, doctors, medical staff, and the hospitals for their cooperation and support in taking the Phase III trials forward in 26,000 volunteers in India,” Bharat Biotech Joint Managing Director Suchitra Ella said.

The company continues its progress towards achieving the goal of 26,000 participants for Phase-3 clinical trials of Covaxin, she added.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

BRS has no plans to contest K’taka Assembly polls: Kumaraswamy

Karnataka govt to open ‘Namma Clinics’ in the state

Hindi trailer of Rishab Shetty-starrer ‘Kantara’ ready for release on Oct 9

India’s heaviest rocket to make global foray on October 22

SA score 249 for 4 against India in rain-curtailed first ODI

BJP to hold mega events, tour programmes of key party leaders ahead of elections in Karnataka

‘Even my wife doesn’t scold me as much as LG sahib’: Kejriwal asks Saxena to ‘chill a bit’


Related Articles More

Foreign vessel with drugs seized off Kochi coast

Newly launched Mumbai-Gandhinagar Vande Bharat train suffers minor damage after hitting buffaloes

‘Even my wife doesn’t scold me as much as LG sahib’: Kejriwal asks Saxena to ‘chill a bit’

What steps can ensure safety on roads, asks HC citing bus mishap

No loss of interest for EPF subscribers: FinMin

MUST WATCH

Running Reace with Rahul Gandi and Siddaramiah

Uchila Dasara 2022 : Final Preparation for Precession

Bharath Judo : Rahul Gandhi Speach in Rain

Day 8 | Mahagauri

Sarapady Devadas Special Video.


Latest Additions

UNHRC adopts resolution against Sri Lanka’s rights record; India abstains from voting

Foreign vessel with drugs seized off Kochi coast

BRS has no plans to contest K’taka Assembly polls: Kumaraswamy

Karnataka govt to open ‘Namma Clinics’ in the state

Gold worth Rs 38.53 Lakhs seized from passenger at MIA

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.